Volume 20, Number 6—June 2014
Research
Human Polyomavirus 9 Infection in Kidney Transplant Patients
Figure 2

Figure 2. Human polyomavirus 9 (HPyV9) seropositivity and seroreactivity in samples from transplant patients and healthy blood donor controls collected 1 year apart, the NetherlandsBlack bars, baseline samples; white bars, follow-up samples (Table 2)Values below bars indicate nopersons positive/total notestedA) Seropositivity percentages for transplant patients and controls; B) seroreactivity levels for transplant patients and controls; C) seropositivity percentages for kidney transplant and kidney–pancreas transplant patients; D) seroreactivity levels for kidney transplant and kidney–pancreas transplant patientsMFI, median fluorescent intensity*Borderline significant (0.05<p<0.100); †significant (p<0.05).